CH258182A - Process for the preparation of a new oxyhydrophenanthrene derivative. - Google Patents

Process for the preparation of a new oxyhydrophenanthrene derivative.

Info

Publication number
CH258182A
CH258182A CH258182DA CH258182A CH 258182 A CH258182 A CH 258182A CH 258182D A CH258182D A CH 258182DA CH 258182 A CH258182 A CH 258182A
Authority
CH
Switzerland
Prior art keywords
methyl
derivative
ethyl
phenanthrene
new
Prior art date
Application number
Other languages
German (de)
Inventor
Aktiengesellschaft Ciba
Original Assignee
Ciba Geigy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy filed Critical Ciba Geigy
Publication of CH258182A publication Critical patent/CH258182A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/30Unsaturated compounds
    • C07C62/32Unsaturated compounds containing hydroxy or O-metal groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Description

  

  Verfahren zur     Herstellung    eines neuen     Oxyhydrophenanthren-Derivates.       Es     wurde    gefunden, dass man zu einem  neuen     Oxyhydrophenant.hren-Derivat    gelan  gen kann, wenn man die     1-Äthyl-2-methyl-7-          oxy-1,2,3,4-tetrahyrlro-phena-nthren-2-car        bon-          säure    mit einem     veresternden    Mittel behan  delt, das die     Hydroxylgruppe    in     7-Stellung     in die     Propionyloxygrup-p:e        überrführt.     



  Das noch nicht     bekannte    Endprodukt des  Verfahrens, die     1-Äthyl    - 2     -methyl    - 7 -     prto-          pionyloxy        -1,2,3,4    -     tetrahydro-phenanthren-2-          carbonsäure,        zeigt    sowohl bei     parenteraler    als  auch bei oraler     Applikation    eine     ausserordent-          Dich    hohe     oestrogene    Wirkung.

   Es     soll    thera  peutische Verwendung finden oder als Zwi  schenprodukt     zur        Herstellung        therapeutisch          verwendbarer        Verbindungen    dienen.  



  Für die     Überführung    der     Hydroxylgruppe     in     7-Stellung    in die     Propionyl'oxygruppe    ver  wendet man     Propionssäure    bzw. ihre Derivate,  wie z. B.     Propionsäureanhydrid    oder     Pro-          pionylchlorid.        Vorteilhaft        arbeitet    man in  Gegenwart von Kondensationsmitteln und/  oder     Katalysatoren.     



  Der Ausgangsstoff wird z. B. erhalten  aus dem 7-Methoxy-l-keto-2-methyl-1,2,3,4       tetrahydro-phenanthren-2-ca,nbons@äuremethyl'-          ester    durch     Grignardierung    mit     einem        Athyl-          mabnesiumhalogenid,        Wasserabspaltung    aus  dem erhaltenen     Carbinol,        Venseifung    der       2-Carbonsäuremethylester-    und der     7-Meth-          oxy-Grupp    e und     Hydrierung    der Äthylen  doppelbindung.

           Beispiel:     1     Gewichtsteil        1-Äthyl-    2     -methyl    - 7     -oxy-          1,2,3,4-Wrahydno-phenanthren-2-carbonsäur-e     der Formel  
EMI0001.0064     
    erwärmt man in einer     Mischung    von 10     Vo-          lumteilen        Pyrid'in    und 5     Volumteilen    Pro  pionsäureanhydrid während 4-5     Stunden     auf dem     Wassenbad.    Nach dem Erkalten  wird Wasser     zugegeben,

      mit Äther     ausge-          schüttelt    und der Äther mit Salzsäure, Bi  carbonätlösung und Wasser gewaschen. Der  Rückstand     der        verdampften        Äthenl'ösung     liefert, nach     Umkrietallisieren    aus verdünn  tem Alkohol, die     oestrogen    wirksame     1-Äthyl-          2-methyl    - 7     -propionylioxy-1,2,3,4-tetno.hydro-          phenanthren-2-#carbons#äure    der Formel  
EMI0001.0084     
    Den     Ausgangsstoff    erhält man z.

   B. wie  folgt: 6,5     Gewichtsteile        1-geto-2-methyl-7-          methogy    -1,2,3,4-     tetrahydro-phenanthren-        2-          carbons@äunemethylester        l:

  ässt    man mit einer           Grignardlösung,        hergestellt    aus 0,6 Gewichts  teilen Magnesium und 2     Volumteilen        Athyl-          bromid,    reagieren, erwärmt 6     Gewichtsteile     des so erhaltenen     Carbinols,    vom F. 153        zwecks        Wassembspaltung        mit    25     Vol'um-          teilen        Ameisensäure    auf :

  dem Wasserbad,  verseift die     Carbonsäuremethylestear    und  die     Methogy-Gruppe    durch Erhitzen von  5     Gewichtsteilen        Wasserabspaltungsprodukt          (1-Äthyliden    - 2 -     methyl    - 7 -methogy-1,2,3,4       tetrahydno-phenantb,ren-2-carbonsäuremethyl-          ester)

      in einer Mischung von 25 Gewichts  teilen     galiumhydroxyd    und 50     Volumteilen     Alkohol im     Einschlussrohr    auf 190-210  und       hydriert    2     Gewichtsteile    der     ungesättigten          Ogysäure        in    100     Volumteilen        In-Natron-          lauge    in Gegenwart von 2 Gewichtsteilen eines       Nickelkatalysators    zur 1-Äthyl-2-methyl-7       oxy-1,2,3,4-tetrahydro-phenanthren-2-carbon-          sä.ure    vom F. 204 .



  Process for the preparation of a new oxyhydrophenanthrene derivative. It has been found that a new Oxyhydrophenant.hren derivative can gelan conditions if the 1-ethyl-2-methyl-7-oxy-1,2,3,4-tetrahyrlro-phena-nthren-2-car bon acid treated with an esterifying agent that converts the hydroxyl group in the 7-position into the propionyloxy group-p: e.



  The as yet unknown end product of the process, 1-ethyl-2-methyl-7-propionyloxy-1,2,3,4-tetrahydro-phenanthrene-2-carboxylic acid, shows an extraordinary effect both on parenteral and oral administration - You have high estrogenic effects.

   It should find therapeutic use or serve as an inter mediate product for the preparation of therapeutically useful compounds.



  For the conversion of the hydroxyl group in the 7-position in the Propionyl'oxygruppe ver used propionic acid or its derivatives, such as. B. propionic anhydride or propionyl chloride. It is advantageous to work in the presence of condensing agents and / or catalysts.



  The starting material is z. B. obtained from the 7-methoxy-l-keto-2-methyl-1,2,3,4 tetrahydro-phenanthrene-2-ca, nbons @ auremethyl'- ester by Grignardation with an ethyl magnesium halide, elimination of water from the obtained Carbinol, soaping of the 2-carboxylic acid methyl ester and the 7-methoxy group and hydrogenation of the ethylene double bond.

           Example: 1 part by weight of 1-ethyl-2-methyl-7 -oxy-1,2,3,4-wrahydno-phenanthrene-2-carboxylic acid of the formula
EMI0001.0064
    it is heated in a mixture of 10 parts by volume of pyridine and 5 parts by volume of propionic anhydride for 4-5 hours on a water bath. After cooling, water is added,

      shaken out with ether and the ether washed with hydrochloric acid, bicarbonate solution and water. The residue of the evaporated Äthenl'ösung provides, after recrystallization from dilute alcohol, the estrogenic 1-ethyl-2-methyl-7-propionylioxy-1,2,3,4-tetno.hydro- phenanthrene-2- # carbons # acid of the formula
EMI0001.0084
    The starting material is obtained z.

   B. as follows: 6.5 parts by weight of 1-geto-2-methyl-7-methogy -1,2,3,4-tetrahydro-phenanthrene-2-carboxylic acid methyl ester 1:

  If one reacts with a Grignard solution made from 0.6 parts by weight of magnesium and 2 parts by volume of ethyl bromide, 6 parts by weight of the carbinol thus obtained, of F. 153, are heated with 25 parts by volume of formic acid for the purpose of water splitting:

  the water bath, saponify the methyl carboxylic acid and the methogy group by heating 5 parts by weight of the dehydration product (1-ethylidene - 2 - methyl - 7-methogy-1,2,3,4 tetrahydno-phenantb, methyl ren-2-carboxylate)

      in a mixture of 25 parts by weight of galium hydroxide and 50 parts by volume of alcohol in the containment tube to 190-210 and hydrogenated 2 parts by weight of the unsaturated ogyic acid in 100 parts by volume of sodium hydroxide solution in the presence of 2 parts by weight of a nickel catalyst to form 1-ethyl-2-methyl-7 oxy-1,2,3,4-tetrahydro-phenanthrene-2-carboxylic acid from F. 204.

 

Claims (1)

PATENTANSPRUCH: Verfahren zur Herstellung eines neuen Oxyhydnophenanthren-Derivates:, :dadurch ge- kennzeichnet, dass man die 1-Äthyl-2-methyl- 7 - ogy - 1,2,3,4 - tetrahydro - phenanthren - 2 - carbonsäure mit einem veresternden Mittel behandelt, PATENT CLAIM: Process for the production of a new oxyhydnophenanthrene derivative :,: characterized in that the 1-ethyl-2-methyl- 7 - ogy - 1,2,3,4 - tetrahydro - phenanthrene - 2 - carboxylic acid with a treated esterifying agents, das die Hydroxylgruppe in 7-Stel- lung i .die Propianyloxygnuppe überführt. Das noch nicht bekannte Endprodukt des Verfahrens, die 1-Äthyl.-2-methyl-7-pro- pionylogy -1,2, 3,4 - tetrahydro-phenanthren-2- carbonsäure, which converts the hydroxyl group in the 7-position i .the propianyloxyn group. The as yet unknown end product of the process, the 1-ethyl-2-methyl-7-propionylogy -1,2, 3,4 - tetrahydro-phenanthrene-2-carboxylic acid, zeigt sowohl bei parenteraler als auch bei oraler Applikation eine ausserArdent- lich hohe oestrogene Wirkung. Es soll thera:- peutisehe Verwendung finden oder als Zwi schenprodukt zu,n Herstellung therapeutisch verwendbarer Verbindungen dienen. L?NTERANSPRüCHE 1. shows an extraordinarily high estrogenic effect on both parenteral and oral administration. It should be used thera: - therapeutically or as an intermediate product for the production of therapeutically usable compounds. LONGER CLAIMS 1. Verfahren nach Patentanspruch, da durch gekennzeichnet, dass man als verestern des Mittel. PropionsÄureanhydrid verwendet. 2. Verfahren nach Patentanspruch. da durch gekennzeichnet, dass man als verestern- des Mittel' Proipionylchlovid verwendet. Method according to claim, characterized in that one is used as esterification of the agent. Propionic anhydride is used. 2. Method according to claim. characterized in that the esterifying agent used is propionylchlovid.
CH258182D 1944-01-10 1944-01-10 Process for the preparation of a new oxyhydrophenanthrene derivative. CH258182A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH258182T 1944-01-10
CH250373T 1944-01-10

Publications (1)

Publication Number Publication Date
CH258182A true CH258182A (en) 1948-11-15

Family

ID=25729438

Family Applications (1)

Application Number Title Priority Date Filing Date
CH258182D CH258182A (en) 1944-01-10 1944-01-10 Process for the preparation of a new oxyhydrophenanthrene derivative.

Country Status (1)

Country Link
CH (1) CH258182A (en)

Similar Documents

Publication Publication Date Title
DE1543427C3 (en)
CH509297A (en) Progestational and deciduogenic 17alpha-substituted-11
CH258182A (en) Process for the preparation of a new oxyhydrophenanthrene derivative.
CH258191A (en) Process for the preparation of a new oxyhydrophenanthrene derivative.
CH250373A (en) Process for the preparation of a new oxyhydrophenanthrene derivative.
CH258185A (en) Process for the preparation of a new oxyhydrophenanthrene derivative.
CH258184A (en) Process for the preparation of a new oxyhydrophenanthrene derivative.
CH258190A (en) Process for the preparation of a new oxyhydrophenanthrene derivative.
CH258187A (en) Process for the preparation of a new oxyhydrophenanthrene derivative.
CH258183A (en) Process for the preparation of a new oxyhydrophenanthrene derivative.
CH258188A (en) Process for the preparation of a new oxyhydrophenanthrene derivative.
CH250807A (en) Process for the preparation of a new oxyhydrophenanthrene derivative.
CH250806A (en) Process for the preparation of a new oxyhydrophenanthrene derivative.
CH257400A (en) Process for the preparation of a new oxy-octahydrophenanthrene derivative.
CH258189A (en) Process for the preparation of a new oxyhydrophenanthrene derivative.
CH258192A (en) Process for the preparation of a new oxyhydrophenanthrene derivative.
CH227069A (en) Process for the preparation of a cyclopentano-dimethyl-polyhydrophenanthrene-carboxylic acid.
CH258186A (en) Process for the preparation of a new oxyhydrophenanthrene derivative.
CH258180A (en) Process for the preparation of a new oxyhydrophenanthrene derivative.
CH250808A (en) Process for the preparation of a new oxyhydrophenanthrene derivative.
AT160824B (en) Process for the preparation of unsaturated oxyketones of the cyclopentanopolyhydrophenanthrene series.
CH258181A (en) Process for the preparation of a new oxyhydrophenanthrene derivative.
AT250581B (en) Process for the preparation of 2α-methylandrostane derivatives
CH263483A (en) Process for the preparation of a new oxyhydrophenanthrene derivative.
CH242609A (en) Process for the preparation of a new oxyhydrophenanthrene derivative.